Mineralys Therapeutics, Inc.

FRC's fair value estimate for Mineralys Therapeutics, Inc., and the rating behind it. MLYS last traded at $28.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Valuation, profitability, liquidity and leverage ratios for Mineralys Therapeutics, Inc.. Starting points for Mineralys Therapeutics, Inc.: EPS -$4.13, beta 0.68 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend history, yield and payout sustainability for Mineralys Therapeutics, Inc.. Mineralys Therapeutics, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Reported vs. expected earnings history for Mineralys Therapeutics, Inc.. Trailing twelve-month EPS for Mineralys Therapeutics, Inc. stands at -$4.13. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Income statement, balance sheet and cash flow history for Mineralys Therapeutics, Inc.. Mineralys Therapeutics, Inc. has reported as a listed company since 2023. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Mineralys Therapeutics, Inc. valued side by side against its closest peers. Mineralys Therapeutics, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Which institutions hold Mineralys Therapeutics, Inc., and how their positions are changing. At a $2.49B market value, institutional positions materially move Mineralys Therapeutics, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Buying and selling by Mineralys Therapeutics, Inc. executives and directors. Shares of Mineralys Therapeutics, Inc. have traded between $8.24 and $47.65 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

U.S. Senate disclosures naming Mineralys Therapeutics, Inc.. Mineralys Therapeutics, Inc. is a $2.49B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

U.S. House of Representatives disclosures naming Mineralys Therapeutics, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

Latest headlines and company announcements for Mineralys Therapeutics, Inc.. Coverage tracks Mineralys Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.